Wegovy Import: Current Status, Challenges, and How to Obtain High-Dose 2.4mg | TASAKI PHAMA

Introduction: What is Wegovy?

Wegovy, known generically as Semaglutide, is a medication for treating obesity. Developed by the Danish pharmaceutical company Novo Nordisk, it is classified as a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone secreted from the small intestine after meals, promoting insulin secretion to lower blood sugar levels and suppress appetite.

Wegovy supports weight loss in obese patients when used in conjunction with diet and exercise. Its effectiveness is particularly expected for obese patients with a BMI (Body Mass Index) of 30 or higher, or those with a BMI of 27 or higher and complications such as hypertension, type 2 diabetes, or dyslipidemia.

Wegovy is provided as a subcutaneous injection and is usually administered once a week. The dosage is gradually increased according to the patient’s condition. In Japan, a lower-dose Semaglutide formulation has been approved as a treatment for type 2 diabetes, but high-dose Wegovy is not approved.

Necessity of High-Dose Wegovy (2.4mg) and Overseas Status

Wegovy starts at 0.25mg and is gradually increased every 4 weeks to 0.5mg, 1.0mg, and 1.7mg, eventually reaching a maintenance dose of 2.4mg. The high dose of 2.4mg is expected to have a more potent appetite-suppressing and weight-loss effect, making it particularly important for patients with severe obesity.

In the United States, the FDA (Food and Drug Administration) approved Wegovy as an obesity treatment in 2021. In Europe, the EMA (European Medicines Agency) has also approved it, and it is used in many countries. Clinical trials have shown that Wegovy 2.4mg has a significant weight loss effect compared to placebo and contributes to reducing the risk of lifestyle-related diseases.

However, Wegovy 2.4mg is not approved in Japan and cannot be obtained. Therefore, some patients are considering methods such as importing it personally from overseas. However, personal import carries risks regarding quality and safety, so caution is necessary.

For patients with severe obesity, Wegovy 2.4mg can be an effective treatment option when lifestyle improvements alone are not sufficient. However, as an unapproved drug, it should be used with caution under the guidance of a doctor.

BMI Values for Wegovy Indication

Wegovy (Semaglutide 2.4mg) is generally considered appropriate for obese patients who meet the following criteria, in addition to diet and exercise:

• BMI (Body Mass Index) of 30 kg/m² or higher
• BMI of 27 kg/m² or higher and having one or more obesity-related health risks such as hypertension, type 2 diabetes, or dyslipidemia

BMI is calculated as weight (kg) ÷ height (m) ÷ height (m). The higher the BMI, the higher the degree of obesity.

Precautions and Legal Regulations for Wegovy Import

When importing Wegovy from overseas, it is necessary to understand some precautions and legal regulations. First, the personal import of pharmaceuticals is regulated by the Pharmaceuticals and Medical Devices Act. Personal import is allowed, in principle, only when necessary for one’s own treatment.

There are also restrictions on the quantity of pharmaceuticals to be imported, and generally, imports exceeding one month’s supply are not allowed. Furthermore, a doctor’s prescription may be required depending on the pharmaceutical to be imported. In the case of Wegovy, a doctor’s prescription is likely to be required because it is an unapproved drug in Japan.

Even when using a personal import agency, caution is required. It is necessary to choose a reliable agency and be careful of agencies that sell counterfeit or substandard pharmaceuticals. The importer is ultimately responsible for the quality and safety of the pharmaceuticals.

Our company (Tasakin Yakuhin) does not provide pharmaceutical import agency services. We also cannot respond to consultations regarding personal import. If you are considering using Wegovy, be sure to consult a doctor and receive appropriate guidance.

Conclusion: Appropriate Use of Wegovy and Future Prospects

Wegovy (Semaglutide 2.4mg) is a potentially effective option in the treatment of obesity. However, it is not approved in Japan, and there are several hurdles to obtaining it. Personal import carries risks regarding quality and safety, so it should be considered carefully.

If you are considering using Wegovy, be sure to consult a doctor and receive appropriate guidance. In addition to Wegovy, lifestyle improvements such as diet and exercise are essential for treating obesity.

It is hoped that Wegovy will be approved in Japan in the future and can be used appropriately. Obesity is a factor that increases the risk of many lifestyle-related diseases, so appropriate treatment and prevention are important. Along with the development of new drugs like Wegovy, it is desirable to deepen social understanding of obesity.